ALKS-2680
- Generic Name
- ALKS-2680
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
- First Posted Date
- 2025-02-25
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT06843590
- Locations
- 🇺🇸
Alkermes Investigational Site, San Antonio, Texas, United States
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06555783
- Locations
- 🇦🇺
Alkermes Investigator Site, Bedford Park, South Australia, Australia
🇪🇸Alkermes Investigational Site, Madrid, Spain
🇮🇹Alkermes Investigational site, Verona, Italy
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06358950
- Locations
- 🇪🇸
Alkermes Investigational Site, Madrid, Spain
🇦🇺Alkermes Investigator Site, Bedford Park, South Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath